Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

GlobeNewswire March 22, 2023

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

GlobeNewswire December 13, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

GlobeNewswire November 22, 2022

Marker Therapeutics Reports Q3 2022 Operating and Financial Results

GlobeNewswire November 10, 2022

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

GlobeNewswire September 13, 2022

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

GlobeNewswire September 8, 2022

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

GlobeNewswire August 11, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

GlobeNewswire August 4, 2022

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

GlobeNewswire May 13, 2022

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

GlobeNewswire May 4, 2022

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

GlobeNewswire April 26, 2022

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

GlobeNewswire March 17, 2022

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

GlobeNewswire March 7, 2022

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

GlobeNewswire February 16, 2022

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

GlobeNewswire February 8, 2022

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

GlobeNewswire January 19, 2022

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

PR Newswire December 9, 2021

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

PR Newswire November 18, 2021

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

PR Newswire November 10, 2021

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

PR Newswire September 7, 2021